Nucor earnings beat by $0.08, revenue fell short of estimates
LONDON - Indivior PLC (LON:INDV), a pharmaceutical company, has published its 2024 Annual Report and Accounts, providing a comprehensive overview of its financial performance for the year ending December 31, 2024. The report was made available today on the company’s investor relations website.
The detailed financial statement is set to be submitted to the UK Financial Conduct Authority’s National Storage Mechanism, making it accessible for public inspection. This submission is in compliance with the UK Listing Rule 22.2.6R.
Shareholders who prefer physical copies of corporate documents will receive a hard copy of the 2024 Annual Report along with the Notice of Annual General Meeting 2025 (AGM Notice) by March 27, 2025. Those who have not opted for paper communications will be able to access the AGM Notice electronically on the same date.
The publication of the report ensures Indivior’s adherence to the Disclosure Guidance and Transparency Rules (DTRs) set by the FCA. The DTRs mandate issuers to disseminate necessary information for investor awareness and market transparency.
The 2024 Annual Report includes all the required information that must be shared with the media in an unaltered format, as stipulated by the FCA’s regulations.
Indivior PLC, identified by the Legal Entity Identifier code 213800V3NCQTY7IED471, is known for developing medications to treat substance addictions and serious mental illnesses.
The information provided in this article is based on a press release statement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.